BCRX: BioCryst Pharmaceuticals, Inc.
About
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Current Value
$7.161 Year Return
Current Value
$7.161 Year Return
Key Details
Market Cap
$1.49B
P/E Ratio
-11.87
1Y Stock Return
41.37%
1Y Revenue Growth
29.92%
Dividend Yield
0.00%
Price to Book
-3.2
Strategies that include BCRX
Stock's related to BCRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PGEN | 48.33% | $228.91M | -28.00% | 0.00% |
| MARA | 41.09% | $6.39B | +92.63% | 0.00% |
| PLRX | 40.85% | $778.32M | -9.55% | 0.00% |
| ALEC | 39.58% | $377.04M | -19.46% | 0.00% |
| NTLA | 38.52% | $1.44B | -50.35% | 0.00% |
| CPRX | 38.43% | $2.55B | +55.68% | 0.00% |
| CROX | 38.43% | $5.71B | +5.81% | 0.00% |
| RXST | 37.94% | $1.82B | +62.89% | 0.00% |
| SWTX | 37.85% | $2.82B | +79.34% | 0.00% |
| FOLD | 37.73% | $2.84B | -11.52% | 0.00% |
| APLS | 37.41% | $3.61B | -41.27% | 0.00% |
| NVCR | 37.34% | $1.78B | +34.75% | 0.00% |
| RYTM | 37.18% | $3.69B | +79.50% | 0.00% |
| RARE | 36.72% | $4.17B | +16.19% | 0.00% |
| CLSK | 36.58% | $3.65B | +211.70% | 0.00% |
| AORT | 36.56% | $1.13B | +69.69% | 0.00% |
| CNOB | 36.47% | $1.03B | +41.32% | 2.65% |
| RIOT | 36.43% | $4.08B | +9.85% | 0.00% |
| ALEX | 36.16% | $1.41B | +18.14% | 4.59% |
| ARWR | 36.04% | $2.31B | -34.44% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HES | 0.06% | $45.06B | +1.32% | 1.24% |
| MX | -0.09% | $135.79M | -45.52% | 0.00% |
| KR | 0.10% | $42.03B | +35.08% | 2.11% |
| CLX | 0.12% | $20.81B | +20.66% | 2.88% |
| KRRO | -0.14% | $436.84M | +20.68% | 0.00% |
| TPST | 0.17% | $37.75M | -77.59% | 0.00% |
| BEST | 0.20% | $31.65M | +3.88% | 0.00% |
| WHF | 0.22% | - | - | 14.53% |
| GPRK | -0.24% | $440.00M | -9.95% | 6.37% |
| REYN | 0.29% | $5.79B | +3.76% | 3.35% |
| LPLA | -0.34% | $23.55B | +38.13% | 0.38% |
| AZO | 0.34% | $52.52B | +16.10% | 0.00% |
| NAPA | 0.37% | $1.63B | +9.61% | 0.00% |
| MNST | 0.37% | $52.25B | -1.95% | 0.00% |
| KNDI | -0.40% | $96.53M | -60.11% | 0.00% |
| ORLY | -0.41% | $69.31B | +22.06% | 0.00% |
| HRL | 0.41% | $16.30B | -8.38% | 3.81% |
| IBKR | 0.42% | $20.20B | +131.83% | 0.37% |
| TRV | 0.42% | $58.86B | +48.10% | 1.59% |
| SRG | 0.46% | $221.13M | -55.94% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STG | -14.55% | $35.67M | +7.92% | 0.00% |
| GAN | -12.75% | $83.39M | +21.19% | 0.00% |
| HUSA | -12.22% | $16.69M | -11.56% | 0.00% |
| COR | -10.17% | $47.48B | +21.20% | 0.86% |
| SOLV | -9.91% | $11.58B | -16.19% | 0.00% |
| MCK | -8.59% | $78.15B | +35.51% | 0.42% |
| SUN | -8.53% | $7.32B | +1.51% | 6.47% |
| DADA | -8.25% | $367.07M | -63.71% | 0.00% |
| GIS | -7.62% | $34.85B | -2.91% | 3.78% |
| SOC | -7.17% | $1.93B | +74.70% | 0.00% |
| PULM | -6.57% | $19.83M | +202.98% | 0.00% |
| LITB | -6.40% | $35.48M | -75.45% | 0.00% |
| CRTO | -6.29% | $2.10B | +58.23% | 0.00% |
| PRT | -6.27% | $48.72M | -16.56% | 10.33% |
| OXBR | -6.04% | $19.05M | +178.18% | 0.00% |
| WM | -5.95% | $87.92B | +27.58% | 1.34% |
| PGR | -5.84% | $149.10B | +57.29% | 0.45% |
| STNG | -5.83% | $2.96B | +0.87% | 2.75% |
| PRPO | -5.39% | $9.10M | -13.65% | 0.00% |
| BTCT | -5.22% | $42.61M | +353.33% | 0.00% |
ETF's related to BCRX
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GBIL | -0.03% | $5.60B | 0.12% |
| FTGC | -0.05% | $2.17B | 1.02% |
| FLTR | -0.22% | $1.79B | 0.14% |
| DBMF | -0.34% | $1.02B | 0.85% |
| XHLF | 0.37% | $874.27M | 0.03% |
| AGZD | -0.49% | $142.76M | 0.23% |
| CORN | -0.53% | $61.12M | 0.2% |
| ICLO | 0.64% | $209.30M | 0.2% |
| XBIL | 0.77% | $637.70M | 0.15% |
| FLRN | 0.93% | $2.33B | 0.15% |
| CSHI | -1.18% | $482.85M | 0.38% |
| CANE | 1.32% | $17.72M | 0.29% |
| BSCO | 1.58% | $2.35B | 0.1% |
| FMF | -1.60% | $244.61M | 0.95% |
| SOYB | 1.78% | $27.32M | 0.22% |
| WEAT | 1.83% | $120.27M | 0.28% |
| GCC | 1.88% | $133.23M | 0.55% |
| HDRO | -1.93% | $164.26M | 0.3% |
| PREF | 1.94% | $999.92M | 0.55% |
| DBC | -1.99% | $1.39B | 0.87% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -32.34% | $388.04M | 1.43% |
| USDU | -15.24% | $201.97M | 0.5% |
| UUP | -13.41% | $309.25M | 0.77% |
| DBO | -13.28% | $217.57M | 0.77% |
| VIXY | -13.09% | $195.31M | 0.85% |
| DBE | -12.21% | $50.13M | 0.77% |
| DBA | -11.51% | $755.88M | 0.93% |
| USCI | -10.63% | $185.47M | 1.07% |
| COMT | -10.59% | $829.06M | 0.48% |
| KMLM | -10.39% | $353.87M | 0.9% |
| EQLS | -10.35% | $76.08M | 1% |
| TBIL | -8.06% | $4.38B | 0.15% |
| KRBN | -7.04% | $242.47M | 0.85% |
| CTA | -6.82% | $350.27M | 0.78% |
| THTA | -5.76% | $32.20M | 0.49% |
| GSG | -5.41% | $914.42M | 0.75% |
| CLOI | -5.19% | $715.40M | 0.4% |
| BOXX | -4.88% | $4.43B | 0.1949% |
| JUCY | -3.95% | $324.29M | 0.6% |
| MINT | -3.60% | $11.62B | 0.35% |
News
Yahoo
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. “The positiv
Finnhub
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 -- BioCryst Pharmaceuticals, Inc. today announced that the company plans to present at the following conferences: 2024 Jefferies London Healthcare...
Yahoo
BioCryst ( (BCRX) ) has issued an announcement. BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year revenue guidance to $430-$435 million. The company introduced additional revenue guidance of $443-$448 million including RAPIVAB and achieved a GAAP operating profit of $7.7 million. Advancements in their pipeline include BCX17725 for Netherton syndrome and avoralstat for DME, showcasing significant pr
Yahoo
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2024, as inducements material to each employee entering into empl
Yahoo
BioCryst Pharmaceuticals ( NASDAQ:BCRX ) Third Quarter 2024 Results Key Financial Results Revenue: US$117.1m (up 35...
Yahoo
Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.